Posted by Michael Wonder on 21 Feb 2024
Linvoseltamab BLA for treatment of relapsed/refractory multiple myeloma accepted for FDA priority review
21 February 2024 - Regeneron Pharmaceuticals today announced that the US FDA has accepted for priority review the biologics license application for linvoseltamab to treat adult patients with relapsed/refractory multiple myeloma that has progressed after at least three prior therapies.
The target action date for the FDA decision is 22 August 2024.
